Journal article
Ductal Adenocarcinoma of the Prostate
Cancer, Vol.115(13), pp.2872-2880
07/01/2009
DOI: 10.1002/cncr.24326
PMID: 19402048
Abstract
Ductal or endometrioid adenocarcinoma of the prostate may be a subtype of prostate cancer that is amenable to aggressive local therapeutic strategies. The authors of this report investigated the clinical outcome of patients who had prostate ductal adenocarcinoma after primary radical prostatectomy or radiotherapy. METHODS: The clinical features of 108 patients with locally confined or advanced prostate ductal adenocarcinoma who had undergone primary radical prostatectomy (surgical group, n = 76 men) or no surgery (nonsurgical group, n = 32 men) were evaluated retrospectively. Clinical records were reviewed, and Gleason scores, clinical/pathologic stages, and preoperative prostate-specific antigen levels were examined. The clinical features that were assessed included local recurrence, distant metastasis, and progression-free and overall survival after primary therapy. RESULTS: In the surgical group, patients who had pure ductal prostate cancer survived longer (median, 13.8 years; 95% confidence interval [CI], from 13.8 years to not attained) than patients who had mixed ductal prostate cancer (median, 8.9 years; 95% Cl, from 7.1 years to not attained; P = OS). In addition, the median time to local progression was shorter (2.8 years vs 4.9 years) and the median time to distant metastasis was longer (3.9 years vs 2.0 years) for patients who had pure ductal adenocarcinoma than for patients who had mixed ductal adenocarcinoma of the prostate after surgery, respectively. CONCLUSIONS: The results of this preliminary study suggested that pure ductal prostate adenocarcinoma tends to pursue an indolent clinical course and poses an increased risk for local recurrence. Local control (particularly prostatectomy) may improve the clinical outcome of patients with pure prostate ductal adenocarcinoma. These results need to be confirmed in prospective studies. Cancer 2009;115:2872-80. (C) 2009 American Cancer Society.
Details
- Title: Subtitle
- Ductal Adenocarcinoma of the Prostate
- Creators
- Shi-Ming Tu - Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77030 USAAdriana Lopez - The University of Texas MD Anderson Cancer CenterDan Leibovici - The University of Texas MD Anderson Cancer CenterMehmet A. Bilen - The University of Texas MD Anderson Cancer CenterFerhat Evliyaoglu - The University of Texas MD Anderson Cancer CenterAna Aparicio - The University of Texas MD Anderson Cancer CenterCharles C. Guo - The University of Texas MD Anderson Cancer CenterDeborah A. Kuban - The University of Texas MD Anderson Cancer CenterMarcy M. Johnson - The University of Texas MD Anderson Cancer CenterLouis L. Pisters - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.115(13), pp.2872-2880
- DOI
- 10.1002/cncr.24326
- PMID
- 19402048
- NLM abbreviation
- Cancer
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Publisher
- Wiley
- Number of pages
- 9
- Grant note
- P30 CA016672 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) P30CA016672 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English; Japanese
- Date published
- 07/01/2009
- Academic Unit
- Ophthalmology and Visual Sciences
- Record Identifier
- 9984845393602771
Metrics
5 Record Views